Cladex injection
Dexa Medica
Ingredients in every vial
| Cefotaxime | 1 g |
Each package contains
1 vial of 1 g
Dosage form
 |
injection |
Dosage formInjection
Flavour
None
W.H.O. classification
J01D
J01D
A.T.C. Level 1
Anatomical Main group
J - Antiinfectives for systemic use
J01D
A.T.C. Level 2
Therapeutic subgroup
J01 - Antibacterials for Systemic Use
J01D
A.T.C. Level 3
Pharmacological subgroup
J01D - Other Beta-Lactam Antibacterials in ATC
Available in
 |
The Philippines |
Warnings
Alcohol
CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.
Machinery
CONSULT YOUR DOCTORSafety of this item for use while operating heavy machinery has not been established. Please consult your doctor.
Pregnancy
CONSULT YOUR DOCTORSafety of this item for use during pregnancy has not been established. Please consult your doctor.
Lactation
CAUTIONThis item may not be safe for use during lactation. Use with caution and after consultation with your doctor.
Indication
Infections
Treatment of infections due to susceptible organisms, especially serious and life-threatening infections. These include:
– Brain abscess
– Serious bone and joint infections
– Serious intra-abdominal infections
– Serious gynecological infections (including peritonitis, endometritis, pelvic inflammatory disease, pelvic cellulitis)
– Gonorrhea
– Endocarditis
– Intensive care (selective parenteral and enteral antisepsis regimens)
– Typhoid fever
– Lyme disease
– Meningitis and other central nervous system infections
– Serious lower respiratory tract infections (including pneumonia)
– Bacterial septicemia
– Surgical infections (prophylaxis)
– Serious skin and skin-structure infections
– Serious Urinary Tract Infections
Treatment of infections due to susceptible organisms, especially serious and life-threatening infections. These include:
– Brain abscess
– Serious bone and joint infections
– Serious intra-abdominal infections
– Serious gynecological infections (including peritonitis, endometritis, pelvic inflammatory disease, pelvic cellulitis)
– Gonorrhea
– Endocarditis
– Intensive care (selective parenteral and enteral antisepsis regimens)
– Typhoid fever
– Lyme disease
– Meningitis and other central nervous system infections
– Serious lower respiratory tract infections (including pneumonia)
– Bacterial septicemia
– Surgical infections (prophylaxis)
– Serious skin and skin-structure infections
– Serious Urinary Tract Infections
Dosage
12 YEARS OLD AND ABOVE
1 g every 12 hours, unless otherwise stated.
Moderate to Severe Infections:
1-2 g IV every 6-8 hours.
Severe and Life-threatening Infections:
2 g IV every 4 hours
Maximum daily dose: 12 g
Prevention of post-operative infection:
1 g by IM or IV 30 - 90 minutes before surgery
Caesarean surgery:
1 g IV immediately after the umbilical cord is clamped, and then followed by 1 g IM or IV 6 - 12 hours after the first dose.
Gonorrhea:
1 g IM as a single dose.
Uncomplicated infections:
2 g (1 g every 12 hours, IM or IV)
or
1 g cefotaxime as single dose given IM.
Moderate to severe infections:
3 - 6 g (1 - 2 g every 8 hours IM or IV)
Infections requiring higher dose of antibiotic:
6 - 8 g (2 g every 6 - 8 hours, IV)
Life-threatening infection:
up to 12 g (2 g every 4 hours IV)
0 TO 12 YEARS OLD
Children may be given 100 to 150 mg of cefotaxime per kg body-weight (50 mg/kg for neonates) daily in divided doses at 6 to 12 hours intervals. In life-threatening conditions, this can be increased to 200 mg/kg (150 to 200 mg/kg for neonates).
If larger doses are required, use 2 g of dry powder for injection whereas for babies, premature infants and children, use 0.5 g of preparation.
PATIENTS WITH IMPAIRED RENAL FUNCTION
Patients with creatinine clearance >20 mL/minute/1.73 m² dosage modification is not required. Patients with creatinine clearance <20 mL/minute/1.73 m² dosage modification is required and the frequency of administration depending on the severity of the failure. It is recommended to reduce the dose to ½ the normal dose. Patients undergoing hemodialysis: 0.5 to 2 g daily given as a single dose and additional dose given after each dialysis period.
DURATION OF TREATMENT
The duration of treatment varies depending on the type of infections, but in general, treatment, should usually be continued for at least 48 - 72 hours after fever has subsided or infections have been cured. For infection due to group A ß- hemolytic streptococci, treatment should be continued for at least 10 days to decrease the risks of rheumatic fever or glomerulonephritis.
1 g every 12 hours, unless otherwise stated.
Moderate to Severe Infections:
1-2 g IV every 6-8 hours.
Severe and Life-threatening Infections:
2 g IV every 4 hours
Maximum daily dose: 12 g
Prevention of post-operative infection:
1 g by IM or IV 30 - 90 minutes before surgery
Caesarean surgery:
1 g IV immediately after the umbilical cord is clamped, and then followed by 1 g IM or IV 6 - 12 hours after the first dose.
Gonorrhea:
1 g IM as a single dose.
Uncomplicated infections:
2 g (1 g every 12 hours, IM or IV)
or
1 g cefotaxime as single dose given IM.
Moderate to severe infections:
3 - 6 g (1 - 2 g every 8 hours IM or IV)
Infections requiring higher dose of antibiotic:
6 - 8 g (2 g every 6 - 8 hours, IV)
Life-threatening infection:
up to 12 g (2 g every 4 hours IV)
0 TO 12 YEARS OLD
Children may be given 100 to 150 mg of cefotaxime per kg body-weight (50 mg/kg for neonates) daily in divided doses at 6 to 12 hours intervals. In life-threatening conditions, this can be increased to 200 mg/kg (150 to 200 mg/kg for neonates).
If larger doses are required, use 2 g of dry powder for injection whereas for babies, premature infants and children, use 0.5 g of preparation.
PATIENTS WITH IMPAIRED RENAL FUNCTION
Patients with creatinine clearance >20 mL/minute/1.73 m² dosage modification is not required. Patients with creatinine clearance <20 mL/minute/1.73 m² dosage modification is required and the frequency of administration depending on the severity of the failure. It is recommended to reduce the dose to ½ the normal dose. Patients undergoing hemodialysis: 0.5 to 2 g daily given as a single dose and additional dose given after each dialysis period.
DURATION OF TREATMENT
The duration of treatment varies depending on the type of infections, but in general, treatment, should usually be continued for at least 48 - 72 hours after fever has subsided or infections have been cured. For infection due to group A ß- hemolytic streptococci, treatment should be continued for at least 10 days to decrease the risks of rheumatic fever or glomerulonephritis.